These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 36320259)
21. NIR-Light-Triggered Anticancer Strategy for Dual-Modality Imaging-Guided Combination Therapy via a Bioinspired Hybrid PLGA Nanoplatform. Shen X; Li T; Chen Z; Xie X; Zhang H; Feng Y; Li S; Qin X; Yang H; Wu C; Zheng C; Zhu J; You F; Liu Y Mol Pharm; 2019 Mar; 16(3):1367-1384. PubMed ID: 30776896 [TBL] [Abstract][Full Text] [Related]
22. Biomimetic "Nanoplatelets" as a Targeted Drug Delivery Platform for Breast Cancer Theranostics. Li L; Fu J; Wang X; Chen Q; Zhang W; Cao Y; Ran H ACS Appl Mater Interfaces; 2021 Jan; 13(3):3605-3621. PubMed ID: 33449625 [TBL] [Abstract][Full Text] [Related]
23. Hyaluronate-Based Self-Stabilized Nanoparticles for Immunosuppression Reversion and Immunochemotherapy in Osteosarcoma Treatment. Zhang Y; Yuan T; Li Z; Luo C; Wu Y; Zhang J; Zhang X; Fan W ACS Biomater Sci Eng; 2021 Apr; 7(4):1515-1525. PubMed ID: 33793187 [TBL] [Abstract][Full Text] [Related]
24. Doxorubicin pretreatment enhances FAPα/survivin co-targeting DNA vaccine anti-tumor activity primarily through decreasing peripheral MDSCs in the 4T1 murine breast cancer model. Geng F; Bao X; Dong L; Guo QQ; Guo J; Xie Y; Zhou Y; Yu B; Wu H; Wu JX; Zhang HH; Yu XH; Kong W Oncoimmunology; 2020; 9(1):1747350. PubMed ID: 32363118 [TBL] [Abstract][Full Text] [Related]
25. Chitosan-Dextran sulfate coated doxorubicin loaded PLGA-PVA-nanoparticles caused apoptosis in doxorubicin resistance breast cancer cells through induction of DNA damage. Siddharth S; Nayak A; Nayak D; Bindhani BK; Kundu CN Sci Rep; 2017 May; 7(1):2143. PubMed ID: 28526868 [TBL] [Abstract][Full Text] [Related]
26. Polarization of Tumor-Associated Macrophages by Nanoparticle-Loaded Wei B; Pan J; Yuan R; Shao B; Wang Y; Guo X; Zhou S Nano Lett; 2021 May; 21(10):4231-4240. PubMed ID: 33998789 [TBL] [Abstract][Full Text] [Related]
28. Bioresponsive immune-booster-based prodrug nanogel for cancer immunotherapy. Ma X; Yang S; Zhang T; Wang S; Yang Q; Xiao Y; Shi X; Xue P; Kang Y; Liu G; Sun ZJ; Xu Z Acta Pharm Sin B; 2022 Jan; 12(1):451-466. PubMed ID: 35127398 [TBL] [Abstract][Full Text] [Related]
29. Combination therapy with liposomal doxorubicin and liposomal vaccine containing E75, an HER-2/neu-derived peptide, reduces myeloid-derived suppressor cells and improved tumor therapy. Zamani P; Navashenaq JG; Teymouri M; Karimi M; Mashreghi M; Jaafari MR Life Sci; 2020 Jul; 252():117646. PubMed ID: 32272178 [TBL] [Abstract][Full Text] [Related]
30. Cell membrane-based nanoparticles: a new biomimetic platform for tumor diagnosis and treatment. Li R; He Y; Zhang S; Qin J; Wang J Acta Pharm Sin B; 2018 Jan; 8(1):14-22. PubMed ID: 29872619 [TBL] [Abstract][Full Text] [Related]
31. pH-Triggered Surface Charge Reversed Nanoparticle with Active Targeting To Enhance the Antitumor Activity of Doxorubicin. Du JB; Cheng Y; Teng ZH; Huan ML; Liu M; Cui H; Zhang BL; Zhou SY Mol Pharm; 2016 May; 13(5):1711-22. PubMed ID: 26998644 [TBL] [Abstract][Full Text] [Related]
32. Biomimetic nanotherapy: core-shell structured nanocomplexes based on the neutrophil membrane for targeted therapy of lymphoma. Zhao Q; Jiang D; Sun X; Mo Q; Chen S; Chen W; Gui R; Ma X J Nanobiotechnology; 2021 Jun; 19(1):179. PubMed ID: 34120620 [TBL] [Abstract][Full Text] [Related]
33. Sustained and Long-Term Release of Doxorubicin from PLGA Nanoparticles for Eliciting Anti-Tumor Immune Responses. Kim J; Choi Y; Yang S; Lee J; Choi J; Moon Y; Kim J; Shim N; Cho H; Shim MK; Jeon S; Lim DK; Yoon HY; Kim K Pharmaceutics; 2022 Feb; 14(3):. PubMed ID: 35335852 [TBL] [Abstract][Full Text] [Related]
34. Hydrazide-manganese coordinated multifunctional nanoplatform for potentiating immunotherapy in hepatocellular carcinoma. Hou G; Qian J; Guo M; Xu W; Wang J; Wang Y; Suo A J Colloid Interface Sci; 2022 Dec; 628(Pt B):968-983. PubMed ID: 36037718 [TBL] [Abstract][Full Text] [Related]
35. Biodegradable PLGA implants containing doxorubicin-loaded chitosan nanoparticles for treatment of breast tumor-bearing mice. Kefayat A; Vaezifar S Int J Biol Macromol; 2019 Sep; 136():48-56. PubMed ID: 31195043 [TBL] [Abstract][Full Text] [Related]
36. The chemotherapeutic potential of doxorubicin-loaded PEG-b-PLGA nanopolymersomes in mouse breast cancer model. Alibolandi M; Sadeghi F; Abnous K; Atyabi F; Ramezani M; Hadizadeh F Eur J Pharm Biopharm; 2015 Aug; 94():521-31. PubMed ID: 26170161 [TBL] [Abstract][Full Text] [Related]
37. Tumor microenvironment-activated therapeutic peptide-conjugated prodrug nanoparticles for enhanced tumor penetration and local T cell activation in the tumor microenvironment. Zhu X; Li C; Lu Y; Liu Y; Wan D; Zhu D; Pan J; Ma G Acta Biomater; 2021 Jan; 119():337-348. PubMed ID: 33166712 [TBL] [Abstract][Full Text] [Related]
38. Inducing enhanced immunogenic cell death with nanocarrier-based drug delivery systems for pancreatic cancer therapy. Zhao X; Yang K; Zhao R; Ji T; Wang X; Yang X; Zhang Y; Cheng K; Liu S; Hao J; Ren H; Leong KW; Nie G Biomaterials; 2016 Sep; 102():187-97. PubMed ID: 27343466 [TBL] [Abstract][Full Text] [Related]
39. Tumor Microenvironment-Triggered Charge Reversal Polymetformin-Based Nanosystem Co-Delivered Doxorubicin and IL-12 Cytokine Gene for Chemo-Gene Combination Therapy on Metastatic Breast Cancer. Sun Y; Liu L; Zhou L; Yu S; Lan Y; Liang Q; Liu J; Cao A; Liu Y ACS Appl Mater Interfaces; 2020 Oct; 12(41):45873-45890. PubMed ID: 32924511 [TBL] [Abstract][Full Text] [Related]
40. PEGylated-PLGA Nanoparticles Coated with pH-Responsive Tannic Acid-Fe(III) Complexes for Reduced Premature Doxorubicin Release and Enhanced Targeting in Breast Cancer. Hu F; Zhang R; Guo W; Yan T; He X; Hu F; Ren F; Ma X; Lei J; Zheng W Mol Pharm; 2021 Jun; 18(6):2161-2173. PubMed ID: 32515968 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]